Raise closed, search for fresh raises on Seedstage

Washington, DC

Developing an accessible diagnostic tool to improve maternal health by enabling early detection of preeclampsia.

• Mission: Advancing maternal health through accessible, accurate diagnostic tools for early detection of preeclampsia, aimed at improving outcomes for mothers and infants.  
• Innovation: A rapid, urine-based diagnostic test for preeclampsia, designed for both home and clinical use, offering an affordable and easy-to-use screening tool.  
• Market Opportunity: Addressing maternal health inequities by providing a preventive solution for preeclampsia, a critical pregnancy complication, particularly in underserved regions.  
• Funding Uses: Bringing the diagnostic tool to market, focusing on regulatory approvals and initial launches in the U.S. and South Africa.  
• Social Impact: Empowering women and birthing people to proactively manage their health and reduce complications associated with undiagnosed preeclampsia.  
• Global Vision: Expanding access to maternal health diagnostics globally, with plans for broad distribution to address gaps in prenatal care and reduce healthcare disparities.  

Kalia Health is a biotechnology company focused on advancing maternal health through accessible, accurate diagnostic tools, specifically for preeclampsia. Positioned as a pre-revenue, pre-regulatory-approval organization, Kalia Health is in the final stages of developing a rapid, urine-based diagnostic test that enables early detection and intervention for preeclampsia. This test, designed for both home and clinical use, aims to address maternal health inequities by providing an accessible screening tool to those at risk, ultimately improving outcomes for mothers and their infants globally.

Through this fundraising offering, Kalia Health seeks to bring this innovative diagnostic technology to market, with plans to launch initially in the U.S. and South Africa, pending regulatory approvals. The company envisions empowering women and birthing people to manage their health proactively, reducing complications associated with undiagnosed preeclampsia. By making this diagnostic available, Kalia Health aims to contribute to a healthcare model that is inclusive, preventive, and centered on patient empowerment.

Company Info

Kalia Health develops diagnostic tools for early detection of preeclampsia to improve maternal health.

Kalia Health is a biotechnology company focused on enhancing maternal health worldwide through accessible and safe diagnostic solutions. The company is in the advanced stages of developing a point-of-care diagnostic tool designed for early detection of preeclampsia, a serious pregnancy complication. This innovative test allows women and birthing people to self-screen for preeclampsia at home or in clinical settings, empowering individuals to seek timely medical intervention. Although Kalia Health has made significant progress, including a prototype and clinical trials in South Africa, the product has yet to receive FDA approval and is not currently available for use.

With a dedicated team of experts, Kalia Health is working toward regulatory approval, aiming to launch initially in the U.S. and South Africa, with further expansion plans in global markets. Through its diagnostic tool, the company seeks to address the gap in prenatal care by providing a cost-effective, easy-to-use solution that could improve outcomes in maternal health and reduce healthcare disparities.